

**This item is the archived preprint of:**

Analysis of Wilms' tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed

**Reference:**

Gielis Sofie, Flumens Donovan, van der Heijden Sanne, Versteven Maarten, De Reu Hans, Bartholomeus Esther, Schippers Jolien, Campillo Davó Diana, Berneman Zwi Nisan, Anguille Sébastien, ....- Analysis of Wilms' tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed  
bioRxiv, 2023, 24 p.

Full text (Publisher's DOI): <https://doi.org/10.1101/2023.11.26.568717>

To cite this reference: <https://hdl.handle.net/10067/2033310151162165141>

## **Analysis of Wilms' tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed**

**Sofie Gielis<sup>1,2,3</sup>, Donovan Flumens<sup>4</sup>, Sanne van der Heijden<sup>4,5</sup>, Maarten Versteven<sup>4</sup>, Hans De Reu<sup>4</sup>,  
Esther Bartholomeus<sup>2,8,9</sup> Jolien Schippers<sup>6</sup>, Diana Campillo-Davo<sup>4</sup>, Zwi N. Berneman<sup>4,10</sup>, Sébastien  
Anguille<sup>4,10,11</sup>, Evelien Smits<sup>2,5,10</sup>, Benson Ogunjimi<sup>2,7,8,9</sup>, Eva Lion<sup>2,4,10</sup>, Kris Laukens<sup>1,2,3</sup>, Pieter  
Meysman<sup>1,2,3\*</sup>**

<sup>1</sup> Adrem Data Lab, Department of Computer Science, University of Antwerp, Antwerp, Belgium

<sup>2</sup> Antwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS),  
University of Antwerp, Antwerp, Belgium

<sup>3</sup> Biomedical Informatics Research Network Antwerp (Biomina), University of Antwerp, Antwerp,  
Belgium

<sup>4</sup> Laboratory of Experimental Hematology (LEH), Vaccine & Infectious Disease Institute (VAXINFECTIO),  
Faculty of Medicine and Health Sciences, University of Antwerp, Edegem, Belgium

<sup>5</sup> Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network  
(IPPON), University of Antwerp, Wilrijk, Belgium

<sup>6</sup> Genetics, Pharmacology and Physiopathology of Heart, Blood Vessels and Skeleton (GENCOR)  
department, University of Antwerp, Edegem, Belgium

<sup>7</sup> Department of Paediatrics, Antwerp University Hospital, Edegem, Belgium

<sup>8</sup> Centre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Vaccine and  
Infectious Disease Institute, University of Antwerp, Wilrijk, Belgium

<sup>9</sup> Antwerp Center for Translational Immunology and Virology (ACTIV), Vaccine and Infectious Disease  
Institute, University of Antwerp, Wilrijk, Belgium

<sup>10</sup> Center for Cell Therapy & Regenerative Medicine (CCRG), Antwerp University Hospital, Edegem,  
Belgium

<sup>11</sup> Division of Hematology, Antwerp University Hospital, Edegem, Belgium

\*Corresponding author ([pieter.meysman@uantwerpen.be](mailto:pieter.meysman@uantwerpen.be))

## Abstract

The Wilms' tumor protein 1 (WT1) is a well-known and prioritized tumor-associated antigen expressed in numerous solid and blood tumors. Its abundance and immunogenicity have led to the development of different WT1-specific immune therapies. The driving player in these therapies, the WT1-specific T-cell receptor (TCR) repertoire, has received much less attention. Importantly, T cells with high affinity against the WT1 self-antigen are normally eliminated after negative selection in the thymus and are thus rare in peripheral blood. Here, we developed computational models for the robust and fast identification of WT1-specific TCRs from TCR repertoire data. To this end, WT1<sub>37-45</sub> (WT1-37) and WT1<sub>126-134</sub> (WT1-126)-specific T cells were isolated from WT1 peptide-stimulated blood of healthy individuals. The TCR repertoire from these WT1-specific T cells was sequenced and used to train a pattern recognition model for the identification of WT1-specific TCR patterns for the WT1-37 or WT1-126 epitopes. The resulting computational models were applied on an independent published dataset from acute myeloid leukemia (AML) patients, treated with hematopoietic stem cell transplantation, to track WT1-specific TCRs *in silico*. Several WT1-specific TCRs were found in AML patients. Subsequent clustering analysis of all repertoires indicated the presence of more diverse TCR patterns within the WT1-specific TCR repertoires of AML patients in complete remission in contrast to relapsing patients. We demonstrate the possibility of tracking WT1-37 and WT1-126-specific TCRs directly from TCR repertoire data using computational methods, eliminating the need for additional blood samples and experiments for the two studied WT1 epitopes.

## Introduction

Central in the development of new immunotherapies for patients with acute myeloid leukemia (AML) lies the specific targeting of AML-associated antigens [1], [2]. A specific interest goes to Wilms' tumor protein 1 (WT1) which has an acknowledged role as a tumor oncogene in a variety of malignancies, including AML [2], [3]. As such, WT1 has been identified as a nearly universal tumor-associated antigen (TAA) overexpressed in numerous solid and hematological cancers [4]–[7], and has been listed as the

most interesting cancer antigen for immune therapies [8]. However, as a self-antigen also expressed in healthy tissues, T-cell clones of high affinity are usually eliminated after negative selection in the thymus. Therefore, the frequency of high-affinity T-cell receptors (TCRs) towards WT1-epitopes in circulating T cells is low. It is hypothesized that WT1-targeted immunotherapies might increase the frequency of anti-AML T cells activity resulting in higher survival rates. Many of these therapies are based on activation of WT1-specific T cells targeting cancer cells overexpressing the WT1 antigen. Hence, the success of these immune therapies relies on recognition of the WT1 antigen by the TCR of these WT1-specific T cells. Despite the large interest in WT1, the WT1-specific TCR repertoire in AML patients has not been fully investigated so far.

TCRs are heterodimeric membrane proteins consisting most often of an alpha and a beta chain ( $\alpha\beta$  TCRs), each containing three hypervariable domains called complementary determining region 1 (CDR1), CDR2, and CDR3. The CDRs are in contact with the peptide and/or the major histocompatibility complex (MHC) molecule. Especially the CDR3 alpha and beta regions are important in identifying its epitope partner as these largely interact with the epitope surface [9], [10]. Due to the high diversity of these CDR3 sequences in each TCR repertoire, the immune system is able to recognize a broad spectrum of peptides. This TCR diversity is achieved through TCR gene rearrangement, a process in which discrete segments composing the TCR genes (V and J in the alpha chain, and V, D and J in the beta chain) randomly join by somatic recombination. The introduction of short insertions and deletions at the connections between rearranged genes further increases TCR diversity [11].

TCR sequencing on blood samples and biopsies facilitates the study of the composition of this repertoire. In this sense, to analyze the TCR repertoire of a sample, both bulk and single-cell sequencing are used. While the former strategy is less expensive per T cell, the latter allows the recovery of paired TCR alpha-beta chains. In addition, antigen-specific T cells can be isolated by sorting tetramer-positive T cells specific for certain peptide-MHC complexes [12] with or without concomitant

selection of T cells that upregulate the expression of activation markers such as CD137 [13], [14]. T-cell sorting is followed by TCR sequencing, aiding the study of antigen-specific TCR repertoires. Due to the increasing availability of public epitope-specific TCR data, new methods were designed to circumvent these laborious experiments by focusing on the computational identification of epitope-specific TCRs. This progress was possible since TCRs with similar CDR3 beta sequences are known to often recognize the same epitope [15]. Thus, previously identified epitope-specific TCRs can be used to identify common patterns that underlie the recognition of epitopes by TCRs. This is the basis of tools such as TCRex [16], which use machine learning methods to extract epitope-specific recognition patterns in the TCR CDR3 sequence to predict the epitope specificity for new TCRs. In addition, the finding of shared similar patterns in the sequences of epitope-specific TCRs has led to the development of clustering methods such as clusTCR [17] and ALICE [18]. These allow the identification of potentially epitope-specific clusters by grouping TCRs based on their CDR3 sequence.

In this study, we applied recently developed computational techniques to study the TCR repertoire for two human leukocyte antigen (HLA)-A\*02:01-restricted WT1-derived peptides: WT1<sub>37-45</sub> and WT1<sub>126-134</sub>, hereafter referred to as WT1-37 and WT1-126, respectively [19], [20]. The objective was to train machine learning methods to monitor WT1-specific T-cells in the repertoires of patients with AML.

## **Materials and methods**

A summary of the general workflow is demonstrated in Figure 1. A full description of the materials and methods is present in **Supplemental material S1**.

## **Results**

### **Establishment of a WT1-TCR database from expanded WT1 epitope-specific primary human CD8<sup>+</sup> T cells**

WT1-37-reactive and WT1-126-reactive CD8<sup>+</sup> T-cell clones were successfully expanded using buffy coat preparations by means of two consecutive IVS. After the first IVS with autologous peptide-pulsed monocyte-derived DCs,  $0.29 \pm 0.23\%$  (mean  $\pm$  SD) of viable WT1-37-specific (**Figure 2A**) and  $0.08 \pm 0.11\%$  of WT1-126-specific CD8<sup>+</sup> T cells (**Figure 2B**) were detected with WT1-37 or WT1-126 HLA-A\*02:01 tetramers (WT1-37/HLA-A2 and WT1-126/HLA-A2, respectively). After the second IVS with irradiated autologous peptide-pulsed CD14<sup>+</sup>CD8<sup>-</sup> peripheral blood lymphocytes, both WT1-37-specific and WT1-126-specific T cells significantly increased to  $8.03 \pm 7.66\%$  ( $p=0,0005$ ; **Figure 2A**) and to  $1.13 \pm 1.35\%$  ( $p=0,0469$ ; **Figure 2B**), reflecting a mean 28-fold and 14-fold increase in the frequency of WT1-37-specific and WT1-126-specific CD8<sup>+</sup> T cells, respectively, between the first and the second IVS. Next, the TCR  $\beta$  chains of WT1-37/HLA-A2 and WT1-126/HLA-A2 tetramer-sorted T cells were sequenced. The full list of TCR sequences can be found in **Supplemental material S2**. An overview of the number of raw reads and the number of TCR clonotypes identified by MiXCR is given in **Supplemental material S3**. In total, 1262 and 101 unique TCR  $\beta$  sequences were derived from 12 healthy donors for peptide WT1-37 and seven healthy donors for peptide WT1-126, respectively.

### **WT1-specific TCR sequences from different healthy repertoires cluster together**

In addition to public TCRs that share identical TCR  $\beta$  sequences (**Supplemental material S4**), it is expected to find similar TCR  $\beta$  sequences that only differ in a small number of their amino acids across the WT1-specific repertoires of healthy donors. To evaluate the level of TCR similarity, all WT1-specific CDR3 beta sequences were clustered using clusTCR [17] (**Figure 3**). **Figure 3** depicts clusters for the 411 WT1-37-epitope specific CDR3 beta sequences out of the total 1262 extracted sequences (33%). **Figure 3B** shows clusters for the 34 WT1-126-epitope specific CDR3 beta sequences out of the total 101 extracted sequences (34%). While some clusters are unique to a single donor, many clusters contain TCRs from two or more different donors (69/166 clusters for WT1-37 and 12/16 clusters for WT1-126), indicating that WT1-specific TCRs share similarities within their CDR3 beta sequences across donors (**Figure 3C**). With the exception of the conserved cysteine and phenylalanine at the beginning and the

end of the CDR3 beta sequences, sequence logos (**Supplemental material S5**) show that every other position can be represented by more than one amino acid. There is thus no strict location where the amino acid sequences differ between CDR3 beta sequences of one cluster. Sequence logos also reveal that the varied amino acids at each position are not restricted to a specific group of amino acids, as exemplified in sequence logo **Figure 3C**, position six contains both hydrophobic (cysteine, C) and hydrophilic (arginine, R) amino acids. An overview of the importance and distributions of the V/J genes is given in **Supplemental materials S6-S7**.

### **WT1-specific prediction models can be built with good performance**

The cluster analysis (**Figure 3**) showed the generalizability of the epitope-specific features in the in-house WT1-TCR DB created using samples from healthy donors as starting material. Next, we analyzed whether the WT1-specific TCR repertoire contained enough epitope-specific information in their CDR3 beta sequences to train WT1-specific prediction models with TCRex. TCRex automatically returns common performance metrics using a 5-fold cross-validation strategy (**Supplemental material S8**) and a receiver operating characteristic (ROC) and precision-recall plot for every trained model (**Figure 4**). For the identification of WT1-specific TCRs in independent data, both models were evaluated. The models showed sufficient performance to be used as a predictor for WT1-specific TCRs.

### **WT1-specific TCRs are identified from independent AML patient TCR repertoire data by the trained prediction models**

Two prediction models were trained using TCR beta sequences derived from healthy individuals, one for every WT1 epitope. In order to validate their usability on cancer TCR repertoires, the two models were utilized for the identification of WT1-specific TCRs in cancer patients. For this, we used an independent data set investigating T cells in the bone marrow of AML patients after hematopoietic stem cell transplantation (HSCT) [21]. For both prediction models, WT1-37 and WT1-126 specific TCRs were identified both in one of the healthy individuals and five AML patients, of which two patients



were in relapse and three patients in complete remission. AML patients in remission showed the highest frequency of WT1-specific TCRs (nine identified WT1-specific TCRs), compared to healthy individuals and relapsed patients (three and five, respectively), and contained more unique TCRs having a larger TCR repertoire size (**Table 1**). Two of the identified WT1-specific TCR CDR3s were present both in patients in complete remission as well as in relapse (**Supplemental material S9**).

### **WT1-specific TCR clusters are associated with AML**

In case of peptide-specific T-cell expansion, it is expected to find clusters of highly similar TCRs across repertoires that are reacting to the same peptide-MHC complex [18]. In total, 721 of the 7600 unique CDR3 beta sequences (9,5%) were detected in clusters of similar sequences (**Figure 5A**) from TCR repertoires derived from bone marrow samples from an independent data set [21]. 90 clusters combined TCRs from healthy individuals and AML patients, suggesting substantial overlap between these groups. When considering the seven clusters containing at least one predicted WT1-specific TCR (**Table S10 , Figure 5B**), the majority (39 out of 42) were made up only of sequences that were found in AML patients (**Supplemental material S10**), indicating disease-specificity and (predictive) relevance of WT1-specific TCRs in AML. In the three clusters that included TCRs present in healthy samples, the AML-linked TCRs still dominated. Remarkably, TCRs derived from patients in complete remission were spread out over all seven clusters, while TCRs from relapsing patients were concentrated in only three (**Table S10, Figure 6**), suggesting that displaying more diverse WT1-specific TCR patterns could be associated with remission (chi-squared test,  $p=0.0043$ ).

### **Discussion**

The greater availability of bulk TCR repertoire sequencing has sparked interest in using the TCR repertoire as a multiplexed diagnostic assay [22]. Specificities against a large collection of epitopes can be assessed from the same TCR repertoire using *in silico* annotation models predicting epitope-TCR pairings. Such annotation models require training on previously identified epitope-specific TCRs for

any target epitope, as unseen epitope prediction remains an unsolved problem [23]. However, the limited availability of patient samples for rare malignancies complicates the collection of TCR data for different epitopes. To address this issue, here, we propose a workflow to efficiently isolate WT1-specific TCRs from healthy individuals and train WT1-specificity prediction models. The resulting TCR sequences from *in vitro* expanded T cells from healthy donors showed similarities across donors, which allowed the training and use of WT1-specific models for the identification of WT1-specific TCRs and thus tracking of WT1-specific TCRs in AML patients. By using this approach, we identified more WT1-specific TCRs in the repertoires of the AML patients compared to healthy individuals (12 versus 2). A similar result was found when healthy individuals were vaccinated against Yellow Fever Virus (YFV). Here, the vaccinated repertoires contained more unique YFV-specific TCRs than the pre-vaccinated repertoires [16]. Similar to [24] and [25], we believe that the contact with AML cells stimulates the expansion of WT1-specific TCRs. This is further supported by other studies demonstrating a higher level of WT1-specific T cells in leukemic patients in contrast to healthy individuals [26], [27]. Hence, assessment of WT1-TCR repertoire research as a diagnostic tool for AML might be considered[22].

Along with the annotation of tumor-specific T cells on an individual TCR basis, computational methods are being developed to discover groups of TCRs recognizing the same epitope [17]. These so-called clustering methods were established after the observation that TCRs with similar amino acid sequences frequently show similar epitope specificities [28]–[30]. Big TCR clusters in a repertoire are indicative of a convergent proliferation against a limited set of epitopes and can therefore capture an ongoing or past tumor-specific immune response [18], [31]. During the analysis of potential WT1-specific TCR clusters, we observed that TCRs from relapsed AML patients were more restricted to a limited number of clusters when compared to AML patients in complete remission. Therefore, it is suggested that displaying more diverse WT1-specific patterns, as seen in patients in complete remission, may be associated with a greater protection against relapse. In this sense, it is already known that TCR repertoire diversity plays a role in treatment response. Various studies have shown a link between TCR diversity and response to immune checkpoint inhibitors [32]–[34]. Moreover, a study

on DC-based vaccination has demonstrated an increase in the diversity of the melanoma neoantigen-specific TCR repertoire following treatment [35]. In addition, Rezvani et al. demonstrated that the WT1-specific CD8+ T cells of patients with chronic myelogenous leukemia or AML targeted more WT1-epitopes than healthy volunteers [27]. In that line, our group made an association between the levels of WT1-specific CD8+ T cells targeting different WT1-epitopes and the clinical response of AML patients following a WT1-based dendritic cell vaccine [36], while Hoffman et al. discovered that patients responding to donor lymphocyte infusion (DLI) targeted more leukemia associated epitopes than those who did not respond [37]. Taken together, these data underscore the impact of TCR repertoire diversity in targeting different tumor epitopes. In this study, we identified a relation between the diversity of epitope-specific TCR signatures for individual WT1-epitopes, as defined by the presence of TCRs in WT1-specific clusters, and the response to HSCT. This signal is based on the two WT1-epitopes for which we generated data from healthy individuals, and thus represents a fraction of the overall cellular immunity against the WT1 antigen. Further investigation of the full TCR repertoire is warranted, with an extended coverage of WT1-associated epitopes. Hence, the same protocol can be repeated for other WT1-epitopes resulting in additional prediction models expanding the identification of WT1-specific TCRs.

Overall, we demonstrate that the WT1-specific T-cell repertoire of AML patients holds information regarding response to HSCT therapy. Thus, the WT1-specific TCR repertoire has potential as a promising biomarker for response prediction to cancer treatment and could provide invaluable data for the allocation of personalized immunotherapies to patients that would most likely respond to therapy, especially considering the high costs of personalized immunotherapy. In addition to the absolute count of unique WT1-specific TCRs and the diversity of the WT1-specific TCR repertoire, the activity and function of these T cells may also hold information about the different patient groups. Furthermore, no baseline data was available, thus the presence of the WT1-signal repertoires prior to treatment could not be assessed. This information could provide additional insight into the existence

of biomarkers in the baseline repertoires and their evolution over time, potentially aiding in patient stratification [38]. In conclusion, we have developed a workflow that starts from a robust antigen-specific primary T-cell expansion platform to collect WT1-specific TCRs from the blood of healthy individuals. The collected TCRs were used successfully to train computational models for the identification of WT1-specific TCRs in independent data sets from AML patients. Our workflow revealed differences in the number of unique WT1-specific TCRs and cluster diversity between patients in complete remission and those experiencing relapse. The described platform is extrapolatable to other cancer antigens, enabling the identification of tumor-specific clonotypes within full TCR repertoires. This can aid the research of biomarkers for cancer immunotherapies.

#### **Author contributions**

S.G. performed research, collected data, analyzed and interpreted data and wrote the original manuscript. D.F. performed research, collected data, analyzed and interpreted data and wrote the original manuscript. S. v.d. H. performed research, reviewed and edited the manuscript. M. V. performed research, collected data and reviewed the manuscript. H. D. R. performed research and reviewed the manuscript. E. B. conducted research, analyzed and interpreted the data and reviewed the manuscript. J. S. performed research. D. C. contributed to the interpretation of the results, reviewed and edited the manuscript. Z. N. B. reviewed and edited the manuscript. S. A. reviewed the manuscript. E. S. reviewed and edited the manuscript and supervised the project. B. O. reviewed and edited the manuscript, helped out in research design, conceived the study and supervised the project. E. L. reviewed and edited the manuscript, helped out in research design, conceived the study and supervised the project. K. L. reviewed and edited the manuscript, helped out in research design and supervised the project. P. M. reviewed and edited the manuscript, helped out in research design, conceived the study and supervised the project.

#### **Competing interests**

K.L., P.M. and B.O. hold shares in ImmuneWatch BV, an immunoinformatics company.

## Funding

This work was supported in part by research grants of the Special Research Fund of the University of Antwerp (Small Research Grants ID36379, BOF-KP2018 P.M. and ID41605, Concerted Research Action) and the Methusalem financing program of the Flemish Government to the Antwerp University, the Cellular Therapy Fund from the Antwerp University Hospital (UZA) and UZA Foundation (Belgium), iBOF Project “Modulating Immunity and the Microbiome for Effective CRC Immunotherapy” (MIMICRY) and the public utility foundation Stichting ME TO YOU (Belgium). D.F. was supported by the “Cellular Immunotherapy” grant from the Baillet Latour Fund (Belgium), and an Emmanuel van der Schueren fellowship from Kom op tegen Kanker (KotK, Belgium), followed by a DOCPRO PhD grant of the Special Research Fund (Grant MulTplex). S.G. and M.V. were supported by an SB fellowship from the FWO (S.G. grant 1S48819N, M.V. grant 1S24517N). E.B. and S.v.d.H. were supported via a clinical investigator fellowship from the Research Foundation-Flanders (FWO, Belgium) of B.O. (grant 1861219N). D.C.D. and H.D.R. were supported by grant G053518N from the FWO.

## Data availability statement

Data and scripts used for the analysis are available on github: [https://github.com/sgielis/WT1\\_TCR](https://github.com/sgielis/WT1_TCR). The trained models are available on <https://tcrex.biodatamining.be/>. The original MiXCR files from the healthy volunteers are also available on Zenodo (DOI 10.5281/zenodo.8129250)

## References

- [1] J. Greiner *et al.*, “mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies,” *Int. J. cancer*, vol. 108, no. 5, pp. 704–711, Feb. 2004, doi: 10.1002/ijc.11623.
- [2] S. Anguille, V. F. Van Tendeloo, and Z. N. Berneman, “Leukemia-associated antigens and their

- relevance to the immunotherapy of acute myeloid leukemia,” *Leukemia*, vol. 26, no. 10, pp. 2186–2196, 2012, doi: 10.1038/leu.2012.145.
- [3] H. Goel *et al.*, “Molecular update on biology of Wilms Tumor 1 gene and its applications in acute myeloid leukemia,” *Am. J. Blood Res.*, vol. 10, no. 5, pp. 151–160, 2020.
- [4] S. Nakatsuka *et al.*, “Immunohistochemical detection of WT1 protein in a variety of cancer cells,” *Mod. Pathol.*, vol. 19, no. 6, pp. 804–814, 2006, doi: 10.1038/modpathol.3800588.
- [5] K. Naitoh *et al.*, “Immunohistochemical Analysis of WT1 Antigen Expression in Various Solid Cancer Cells,” *Anticancer Res.*, vol. 36, no. 7, pp. 3715–3724, Jul. 2016.
- [6] X. Qi *et al.*, “Wilms’ tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis,” *Sci. Rep.*, vol. 5, p. 8924, 2015, doi: 10.1038/srep08924.
- [7] H. Sugiyama, “WT1 (Wilms’ Tumor Gene 1): Biology and Cancer Immunotherapy,” *Jpn. J. Clin. Oncol.*, vol. 40, no. 5, pp. 377–387, May 2010, doi: 10.1093/jjco/hyp194.
- [8] M. A. Cheever *et al.*, “The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research,” *Clin. cancer Res.*, vol. 15, no. 17, pp. 5323–5337, Sep. 2009, doi: 10.1158/1078-0432.CCR-09-0737.
- [9] K. C. Garcia and E. J. Adams, “How the T Cell Receptor Sees Antigen—A Structural View,” *Cell*, vol. 122, no. 3, pp. 333–336, 2005, doi: <https://doi.org/10.1016/j.cell.2005.07.015>.
- [10] R. A. Mariuzza, P. Agnihotri, and J. Orban, “The structural basis of T-cell receptor (TCR) activation: An enduring enigma,” *J. Biol. Chem.*, vol. 295, no. 4, pp. 914–925, 2020, doi: [https://doi.org/10.1016/S0021-9258\(17\)49904-2](https://doi.org/10.1016/S0021-9258(17)49904-2).
- [11] E. Market and F. N. Papavasiliou, “V(D)J recombination and the evolution of the adaptive immune system,” *PLoS Biol.*, vol. 1, no. 1, p. E16, Oct. 2003, doi: 10.1371/journal.pbio.0000016.
- [12] G. Dolton *et al.*, “Comparison of peptide–major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells,” *Clin. Exp. Immunol.*, vol. 177, no. 1, pp. 47–63, Jul. 2014, doi: 10.1111/cei.12339.

- [13] M. Wölfl, J. Kuball, M. Eyrich, P. G. Schlegel, and P. D. Greenberg, "Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities," *Cytom. Part A*, vol. 73A, no. 11, pp. 1043–1049, Nov. 2008, doi: <https://doi.org/10.1002/cyto.a.20594>.
- [14] M. Wolf *et al.*, "Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities," *Blood*, vol. 110, no. 1, pp. 201–210, Jul. 2007, doi: [10.1182/blood-2006-11-056168](https://doi.org/10.1182/blood-2006-11-056168).
- [15] P. Meysman, N. De Neuter, S. Gielis, D. Bui Thi, B. Ogunjimi, and K. Laukens, "On the viability of unsupervised T-cell receptor sequence clustering for epitope preference," *Bioinformatics*, vol. 35, no. 9, pp. 1461–1468, 2019.
- [16] S. Gielis *et al.*, "Detection of enriched T cell epitope specificity in full T cell receptor sequence repertoires," *Front. Immunol.*, vol. 10, 2019.
- [17] S. Valkiers, M. Van Houcke, K. Laukens, and P. Meysman, "ClusTCR: a python interface for rapid clustering of large sets of CDR3 sequences with unknown antigen specificity," *Bioinformatics*, vol. 37, no. 24, pp. 4865–4867, Dec. 2021, doi: [10.1093/bioinformatics/btab446](https://doi.org/10.1093/bioinformatics/btab446).
- [18] M. V Pogorelyy *et al.*, "Detecting T-cell receptors involved in immune responses from single repertoire snapshots," *PLoS Biol.*, vol. 17, no. 6, p. e3000314, 2019, doi: [10.1371/journal.pbio.3000314](https://doi.org/10.1371/journal.pbio.3000314).
- [19] D. Campillo-Davo *et al.*, "Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing," *Front. Immunol.*, vol. 9, 2018.
- [20] S. van der Heijden *et al.*, "In vitro expansion of Wilms' tumor protein 1 epitope-specific primary T cells from healthy human peripheral blood mononuclear cells," *STAR Protoc.*, vol. 4, no. 1, p. 102053, 2023, doi: <https://doi.org/10.1016/j.xpro.2023.102053>.
- [21] M. Noviello *et al.*, "Bone marrow central memory and memory stem T-cell exhaustion in AML

- patients relapsing after HSCT," *Nat. Commun.*, vol. 10, no. 1, p. 1065, 2019, doi: 10.1038/s41467-019-08871-1.
- [22] R. A. Arnaout *et al.*, "The Future of Blood Testing Is the Immunome," *Frontiers in Immunology*, vol. 12, 2021.
- [23] P. Moris *et al.*, "Current challenges for unseen-epitope TCR interaction prediction and a new perspective derived from image classification," *Brief. Bioinform.*, vol. 22, no. 4, p. bbaa318, 2021.
- [24] A. Pasetto *et al.*, "Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor.," *Cancer Immunol. Res.*, vol. 4, no. 9, pp. 734–743, Sep. 2016, doi: 10.1158/2326-6066.CIR-16-0001.
- [25] K. Rezvani *et al.*, "Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.," *Blood*, vol. 110, no. 6, pp. 1924–1932, Sep. 2007, doi: 10.1182/blood-2007-03-076844.
- [26] K. Rezvani *et al.*, "Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation," *Blood*, vol. 102, no. 8, pp. 2892–2900, Oct. 2003, doi: 10.1182/blood-2003-01-0150.
- [27] K. Rezvani *et al.*, "T-cell responses directed against multiple HLA-A\*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.," *Clin. cancer Res.*, vol. 11, no. 24 Pt 1, pp. 8799–8807, Dec. 2005, doi: 10.1158/1078-0432.CCR-05-1314.
- [28] P. Meysman, N. De Neuter, S. Gielis, D. Bui Thi, B. Ogunjimi, and K. Laukens, "On the viability of unsupervised T-cell receptor sequence clustering for epitope preference," *Bioinformatics*, vol. 35, no. 9, pp. 1461–1468, 2019, doi: 10.1093/bioinformatics/bty821.
- [29] J. Glanville *et al.*, "Identifying specificity groups in the T cell receptor repertoire," *Nature*, vol.



- 547, no. 7661, pp. 94–98, Jun. 2017, doi: 10.1038/nature22976.
- [30] P. Dash *et al.*, “Quantifiable predictive features define epitope specific T cell receptor repertoires,” *Nature*, vol. 547, no. 7661, pp. 89–93, 2017, doi: 10.1038/nature22383.Quantifiable.
- [31] M. M. Goncharov *et al.*, “Pinpointing the tumor-specific T cells via TCR clusters.,” *Elife*, vol. 11, p. e77274, Apr. 2022, doi: 10.7554/eLife.77274.
- [32] S. A. Hogan *et al.*, “Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.,” *Cancer Immunol. Res.*, vol. 7, no. 1, pp. 77–85, Jan. 2019, doi: 10.1158/2326-6066.CIR-18-0136.
- [33] L. Robert *et al.*, “Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes.,” *Oncoimmunology*, vol. 3, p. e29244, 2014, doi: 10.4161/onci.29244.
- [34] I. Aversa, D. Malanga, G. Fiume, and C. Palmieri, “Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy.,” *Int. J. Mol. Sci.*, vol. 21, no. 7, p. 2378, Mar. 2020, doi: 10.3390/ijms21072378.
- [35] B. M. Carreno *et al.*, “A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells,” *Science (80-. )*, vol. 348, no. 6236, pp. 803–808, May 2015, doi: 10.1126/science.aaa3828.
- [36] S. Anguille *et al.*, “Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia,” *Blood*, vol. 130, no. 15, pp. 1713–1721, Oct. 2017, doi: 10.1182/blood-2017-04-780155.
- [37] S. Hofmann *et al.*, “Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders.,” *Int. J. cancer*, vol. 144, no. 5, pp. 1135–1146, Mar. 2019, doi: 10.1002/ijc.31753.
- [38] S. Valpione *et al.*, “The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival.,” *Nat. Commun.*, vol. 12, no. 1, p. 4098, Jul. 2021, doi:

10.1038/s41467-021-24343-x.

## Tables


**Table 1:** Identified WT1-specific TCRs in AML patients versus healthy donors.

Individual	Disease status	Size of the TCR repertoire	Number of WT1-37 TCRs	Frequency of WT1-37 TCRs (%)	Number of WT1-126 TCRs	Frequency of WT1-126 TCRs (%)
HD1	Healthy	295	0	0	0	0
HD2	Healthy	110	0	0	0	0
HD3	Healthy	931	2	0.215	1	0.107
PT1_CR1	Complete remission	3099	4	0.129	0	0
PT2_CR2	Complete remission	1451	3	0.207	1	0.069
PT3_CR3	Complete remission	102	1	0.980	0	0
PT4_REL1	Relapse	503	0	0	0	0
PT5_REL2	Relapse	592	2	0.338	0	0
PT6_REL3	Relapse	617	2	0.324	1	0.162

For each of the studied individuals, size of the CD4<sup>+</sup>CD8<sup>+</sup> bone marrow TCR repertoire, number and corresponding percentage of identified WT1-TCRs is given for each WT1-epitope individually.


Abbreviations: CR, complete remission; HD, healthy donor; PT, patient; REL, relapse.

## Figures




**Figure 1: Graphical overview of the different methodologies and data sets. (A) Collection of WT1-specific T cells from healthy donors for prediction model training. (1) WT1-specific CD8<sup>+</sup> T cells were expanded from HLA-A\*02:01-positive healthy donor buffy coats by two consecutive *in vitro* stimulations (IVS) [20] and (2) subsequently sorted with epitope-specific MHC class I tetramers. Following TCR  $\beta$  sequencing of the sorted T cells (3), the resulting WT1-specific TCRs were combined into one database (4), referred to as ‘in-house WT1-TCR DB’ and used to train a WT1-37 and WT1-126 TCRex model (5). (B) In-depth analysis of the TCR  $\beta$  sequences derived from the *in vitro* stimulated T**


cells as described in (A). The presence of patterns shared between donors was assessed by (6) identification of public TCRs and (7) clustering of all WT1-specific TCRs for each epitope separately. (8) V/J gene distribution was also assessed in relation to an independent background data set. (C) **Identification of WT1-specific TCRs in the TCR  $\beta$  repertoires of AML patients and healthy donors.** Usability of the trained TCRex models from step (4) was assessed using an independent published data set [21], containing TCR  $\beta$  repertoires from three healthy donors, three AML patients with relapse and three AML patients showing clinical response following hematopoietic stem cell transplantation (HSCT). Using the trained TCRex models, WT1-37-specific (pink) and WT1-126-specific (blue) TCRs were identified in the repertoires of the healthy donors and AML patients (9) and compared between groups (10). Figure created with biorender.com.



**Figure 2: Percentage of expanded WT1-37/HLA-A2 and WT1-126/HLA-A2 tetramer-positive WT1-epitope specific CD8<sup>+</sup> T cells for subsequent fluorescence-activated cell sorting.** Primary peripheral blood CD8<sup>+</sup> T cells from healthy donors were significantly expanded with (A) WT1-37 peptide (n=12, p=0.0005) or (B) WT1-126 peptide (n=7, p=0.0469), in two rounds of IVS (Wilcoxon t-test). Viable WT1-37/HLA-A2 and WT1-126/HLA-A2 tetramer-positive CD8<sup>+</sup> T cells were sorted for RNA extraction and subsequent bulk sequencing. Abbreviations: IVS, *in vitro* stimulation; WT1, Wilms' tumor protein 1. \*, p ≤ 0.05; \*\*\*, p ≤ 0.001.



**Figure 3: Graphs of the clustered WT1-37 (A) and WT1-126 CDR3 beta sequences (B) colored according to the donors. CDR3 beta sequences shared with more than one donor (i.e., public TCRs) are depicted in black. (C) Sequence logo of the largest cluster for WT1-37. In general, the sequence logos summarize the amino acid composition of the CDR3 beta sequences for every cluster (Supplemental material S5). The largest cluster contains 18 CDR3 beta sequences with a length of 13 amino acids. For each of the 13 CDR3 beta positions, the sequence logo summarizes which amino acids appear at these positions in the 18 sequences, while the size of the letters represents the frequency of each amino acid in a particular position. For example, all 18 CDR3 beta sequences contain a cysteine (C) on the first position, while either a serine (S) or a glycine (G) can be present at the fourth position. Since the size of the letter S at position four is much larger than the letter G, most sequences will contain a serine at this position.**




**Figure 4: Receiver operating characteristic (ROC) and precision-recall curves for the trained WT1-37 and WT1-126 TCRex models.** ROC curves visualize the true positive rate (i.e., fraction of the WT1-specific training data set that is correctly classified as WT1-specific by the model) and false positive rate (i.e., fraction of the background data that is wrongly classified as WT1-specific) for all possible classification thresholds for WT1-37 (A) and WT1-126 (C) TCRex models. The precision-recall plots depict the precision at different classification thresholds over the true positive rate for WT1-37 (B) and WT1-126 (D) TCRex models. The precision reflects the proportion of predicted WT1-specific TCRs that is truly WT1-specific and is thus desired to be approximating 1.



**Figure 5: Clustered CDR3 beta repertoires of six AML patients and three healthy individuals from an independent data set [21]. Clusters are colored by (A) response and (B) WT1 specificity. Each colored dot represents a single CDR3 beta sequence. Clusters are defined by at least two connected CDR3 beta sequences.**





**Figure 6: Overview of the WT1-specific TCR clusters.** Letters on the y-axis represent a cluster containing at least a single WT1-specific TCR. On the x-axis, every individual containing at least a single WT1-specific TCR in its repertoire is listed. Out of nine individuals, WT1-specific TCRs were detected in eight individuals. The size of the dots represents the number of TCRs from an individual that are present in that specific cluster, while the color represents the study groups based on disease status: healthy (red), AML patients in complete remission (blue), and relapsed AML patients (yellow). Abbreviations: CR, complete remission; HD, healthy donor; PT, patient; REL, relapse; TCR, T cell receptor; WT1, Wilms' tumor protein 1.